Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Invested Capital (2016 - 2025)

Vanda Pharmaceuticals' Invested Capital history spans 17 years, with the latest figure at $334.7 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 38.42% to $334.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $334.7 million, a 38.42% decrease, with the full-year FY2025 number at $334.7 million, down 38.42% from a year prior.
  • Invested Capital hit $334.7 million in Q4 2025 for Vanda Pharmaceuticals, down from $466.0 million in the prior quarter.
  • Over the last five years, Invested Capital for VNDA hit a ceiling of $544.9 million in Q4 2023 and a floor of $334.7 million in Q4 2025.
  • Historically, Invested Capital has averaged $506.7 million across 5 years, with a median of $513.5 million in 2022.
  • Biggest five-year swings in Invested Capital: grew 12.31% in 2021 and later tumbled 38.42% in 2025.
  • Tracing VNDA's Invested Capital over 5 years: stood at $504.9 million in 2021, then increased by 4.41% to $527.2 million in 2022, then grew by 3.36% to $544.9 million in 2023, then fell by 0.26% to $543.5 million in 2024, then tumbled by 38.42% to $334.7 million in 2025.
  • Business Quant data shows Invested Capital for VNDA at $334.7 million in Q4 2025, $466.0 million in Q3 2025, and $486.3 million in Q2 2025.